- Home
- KRRO vs MRK Comparison
KRRO vs MRK Comparison
Compare KRRO & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRRO | MRK |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.1M | 268.7B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRRO | MRK |
|---|---|---|
| Price | $11.22 | $121.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $54.60 | ★ $121.00 |
| AVG Volume (30 Days) | 294.0K | ★ 14.2M |
| Earning Date | 03-17-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 2.85% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | $7,371,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $145.97 | $5.02 |
| Revenue Next Year | N/A | $5.31 |
| P/E Ratio | ★ N/A | $16.38 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $5.20 | $73.31 |
| 52 Week High | $55.89 | $122.66 |
Technical Indicators
Market Signals| Indicator | KRRO | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 71.39 |
| Support Level | $10.81 | $116.10 |
| Resistance Level | $12.46 | $122.46 |
| Average True Range (ATR) | 1.08 | 3.23 |
| MACD | -0.05 | 0.58 |
| Stochastic Oscillator | 33.02 | 97.40 |
Price Performance
Historical ComparisonAbout KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).